Table 1.
Baseline patient and treatment characteristics
| Variables | |
|---|---|
| Age (median, range) | 47 years (24–75) |
| Stage | |
| IB | 4 (11.4%) |
| IIA | 1 (2.9%) |
| IIB | 26 (74.2%) |
| IIIB | 3 (8.6%) |
| IVA | 1 (2.9%) |
| Pathology | |
| Squamous cell carcinoma | 28 (80%) |
| Adenocarcinoma | 2 (5.7%) |
| Adenosquamous | 5 (14.3%) |
| HPV infection | |
| Positive | 16 (45.7%) |
| Negative | 8 (22.9%) |
| No data | 11 (31.4%) |
| Primary tumor size (median, range) | 4.7 (1.4–11) |
| < 4 cm | 11 (31.4%) |
| ≥ 4 cm | 24 (68.6%) |
| Initial lymph node involvement | |
| Pelvic | 21 (60.0%) |
| Paraaortic | 10 (28.6%) |
| Negative | 8 (22.9%) |
| Initial treatment | |
| Definitive surgery alone | 4 (11.4%) |
| Definitive CCRT | 25 (71.4%) |
| Surgery + PORT | 6 (17.2%) |
| PALN irradiation for initial treatment | 10 (28.6%) |
| Time to PALN recurrence (median, range) | 10.0 months (2.0–50.9) |
| Patterns of PALN recurrence | |
| Isolated PALN recurrence | 14 (40%) |
| Concurrent local recurrence | 8 (22.9%) |
| Concurrent distant metastasis | 13 (37.1%) |
| No. of PALN per patient (median, range) | 2 (1–12) |
HPV, human papilloma virus; CCRT, concurrent chemoradiotherapy; PORT, postoperative radiotherapy